Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to gram-negative bacteria: A retrospective analysis

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 5, 2010, Pages 1742-1748

  Micek, Scott T ^a   Welch, Emily C ^a   Khan, Junaid ^b   Pervez, Mubashir ^b   Doherty, Joshua A ^c   Reichley, Richard M ^c   Kollef, Marin H ^b  

^a BARNES JEWISH HOSPITAL   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Hospital Informatics Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CEFEPIME; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ACINETOBACTER; ADULT; AGED; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; ENTEROBACTER; ESCHERICHIA COLI; FEMALE; GRAM NEGATIVE SEPSIS; HUMAN; INTENSIVE CARE UNIT; KLEBSIELLA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; NEPHROTOXICITY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDY; SEPTIC SHOCK; UNIVERSITY HOSPITAL;

ACINETOBACTER INFECTIONS; ADULT; AGED; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; CARBAPENEMS; CEPHALOSPORINS; COHORT STUDIES; DRUG THERAPY, COMBINATION; ESCHERICHIA COLI INFECTIONS; FEMALE; FLUOROQUINOLONES; GRAM-NEGATIVE BACTERIAL INFECTIONS; HOSPITAL MORTALITY; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PENICILLANIC ACID; PIPERACILLIN; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RETROSPECTIVE STUDIES; SEPSIS; SHOCK, SEPTIC;

EID: 77951217224     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01365-09     Document Type: Article

References (32)

1. Al-Hasan, M. N., J. W. Wilson, B. D. Lahr, K. M. Thomsen, J. E. Eckel- Passow, E. A. Vetter, I. M. Tleyjeh, and L. M. Baddour. 2009. Beta-lactam and fluoroquinolone combination antibiotic therapy for bacteremia caused by gram-negative bacilli. Antimicrob. Agents Chemother. 53:1386-1394.
2. American Thoracic Society and Infectious Diseases Society of America. 2005. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am. J. Respir. Crit. Care Med. 171:388-416.
3. Angus, D. C., W. T. Linde-Zwirble, J. Lidicker, G. Clermont, J. Carcillo, and M. R. Pinsky. 2001. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care Med. 29:1303-1310.
4. Arias, C. A., and B. E. Murray. 2009. Antibiotic-resistant bugs in the 21st century: a clinical super-challenge. N. Engl. J. Med. 360:439-443.
5. Barza, M., J. P. Ioannidis, J. C. Cappelleri, and J. Lau. 1996. Single or multiple daily doses of aminoglycosides: a meta-analysis. BMJ. 312:338-345. (Pubitemid 26049400)
6. Beardsley, J. R., J. C. Williamson, J. W. Johnson, C. A. Ohl, T. B. Karchmer, and D. L. Bowton. 2006. Using local microbiologic data to develop institution-specific guidelines for the treatment of hospital-acquired pneumonia. Chest 130:787-793.
7. Boucher, H. W., G. H. Talbot, J. S. Bradley, J. E. Edwards, D. Gilbert, L. B. Rice, M. Scheld, B. Spellberg, and J. Bartlett. 2009. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48:1-12.
8. Chamot, E., E. Boffi El Amari, P. Rohner, and C. Van Delden. 2003. Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia. Antimicrob. Agents Chemother. 47:2756-2764.
9. Dellinger, R. P., M. M. Levy, J. M. Carlet, J. Bion, M. M. Parker, R. Jaeschke, K. Reinhart, D. C. Angus, C. Brun-Buisson, R. Beale, T. Calandra, J. F. Dhainaut, H. Gerlach, M. Harvey, J. J. Marini, J. Marshall, M. Ranieri, G. Ramsay, J. Sevransky, B. T. Thompson, S. Townsend, J. S. Vender, J. L. Zimmerman, and J. L. Vincent. 2008. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit. Care Med. 36:296-327.
10. Dhainaut, J. F., P. F. Laterre, S. P. LaRosa, H. Levy, G. E. Garber, D. Heiselman, G. T. Kinasewitz, R. B. Light, P. Morris, R. Schein, J. B. Sollet, B. M. Bates, B. G. Utterback, and D. Maki. 2003. The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): role, methodology, and results. Crit. Care Med. 31:2291-2301.
11. Dupont, H., H. Mentec, J. P. Sollet, and G. Bleichner. 2001. Impact of appropriateness of initial antibiotic therapy on the outcome of ventilatorassociated pneumonia. Intensive Care Med. 27:355-362.
12. Freundlich, M., R. W. Thomsen, L. Pedersen, H. West, and H. C. Schønheyder. 2007. Aminoglycoside treatment and mortality after bacteraemia in patients given appropriate empirical therapy: a Danish hospital-based cohort study. J. Antimicrob. Chemother. 60:1115-1123.
13. Garnacho-Montero, J., J. L. Garcia-Garmendia, A. Barrero-Almodovar, F. J. Jimenez-Jimenez, C. Perez-Paredes, and C. Ortiz-Leyba. 2003. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit. Care Med. 31:2742-2751.
14. Harbarth, S., J. Garbino, J. Pugin, J. A. Romand, D. Lew, and D. Pittet. 2003. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am. J. Med. 115:529-535.
15. Heyland, D. K., P. Dodek, J. Muscedere, A. Day, D. Cook, et al. 2008. Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilator-associated pneumonia. Crit. Care Med. 36:737-744.
16. Ibrahim, E. H., G. Sherman, S. Ward, S. V. J. Fraser, and M. H. Kollef. 2000. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 118:146-155.
17. Kihlstrom, E., and L. Andaker. 1985. Inability of gentamicin and fosfomycin to eliminate intracellular Enterobacteriaceae. J. Antimicrob. Chemother. 15:723-728.
18. Klevens, R. M., M. A. Morrison, J. Nadle, S. Petit, K. Gershman, S. Ray, L. H. Harrison, R. Lynfield, G. Dumyati, J. M. Townes, A. S. Craig, E. R. Zell, G. E. Fosheim, L. K. McDougal, R. B. Carey, and S. K. Fridkin. 2007. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 298:1763-1771.
19. Knaus, W. A., E. A. Draper, D. P. Wagner, and J. E. Zimmerman. 1985. APACHE II: a severity of disease classification system. Crit. Care Med. 13:818-829.
20. Kollef, M. H., G. Sherman, S. Ward, and V. J. Fraser. 1999. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 115:462-474.
21. Kollef, M. H. 2008. Broad-spectrum antimicrobials and the treatment of serious bacterial infections: getting it right up front. Clin. Infect. Dis. 47:S3-S13.
22. Kollef, M. H. 2006. Providing appropriate antimicrobial therapy in the intensive care unit: surveillance versus de-escalation. Crit. Care Med. 34:903-905.
23. Leibovici, L., M. Paul, O. Poznanski, M. Drucker, Z. Samra, H. Konigsberger, and S. D. Pitlik. 1997. Monotherapy versus beta-lactam- aminoglycoside combination treatment for gram-negative bacteremia: a prospective, observational study. Antimicrob. Agents Chemother. 41:1127-1133.
24. Micek, S. T., W. Isakow, W. Shannon, and M. H. Kollef. 2005. Predictors of hospital mortality for patients with severe sepsis treated with drotrecogin alfa (activated). Pharmacotherapy 25:26-34.
25. Micek, S. T., A. E. Lloyd, D. J. Ritchie, R. M. Reichley, V. J. Fraser, and M. H. Kollef. 2005. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob. Agents Chemother. 49:1306-1311.
26. Micek, S. T., N. Roubinian, T. Heuring, M. Bode, J. Williams, C. Harrison, T. Murphy, D. Prentice, B. E. Ruoff, and M. H. Kollef. 2006. Before-after study of a standardized hospital order set for the management of septic shock. Crit. Care Med. 34:2707-2713.
27. Paul, M., I. Silbiger, S. Grozinsky, K. Soares-Weiser, and K. Leibovici. 2006. Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst. Rev. 1:CD003344.
28. Paul, M., K. Soares-Weiser, and L. Leibovici. 2003. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis. BMJ 326:1111.
29. Petrosillo, N., E. Ioannidou, and M. E. Falagas. 2008. Colistin monotherapy versus combination therapy: evidence from microbiological, animal and clinical studies. Clin. Microbiol. Infect. 14:816-827.
30. Thiel, S. W., M. F. Asghar, S. T. Micek, R. M. Reichley, J. A. Doherty, and M. H. Kollef. 2009. Hospital-wide impact of a standardized order set for the management of bacteremic severe sepsis. Crit. Care Med. 37:819-824.
31. Trouillet, J. L., J. Chastre, A. Vuagnat, M. L. Joly-Guillou, D. Combaux, M. C. Dombret, and C. Gibert. 1998. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am. J. Respir. Crit. Care Med. 157:531-539.
32. Vidal, L., A. Gafter-Gvili, S. Borok, A. Fraser, and M. Paul. 2007. Efficacy and safety of aminoglycoside monotherapy: systematic review and metaanalysis of randomized controlled trials. J. Antimicrob. Chemother. 60:247-257.